Skip to main content

Investor Relations

We aim to sustain continuous, clear, and trustful communication with all our partners and stakeholders.

Innovative diagnostic solutions for acute and critical care conditions

We are committed to improving patient outcomes with innovative diagnostic solutions for acute and critical care that allow the diagnosis, outcome prediction, and monitoring of patients with acute medical conditions.

SphingoTec develops and markets innovative IVD solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements to routine clinical practice. We develop biomarkers addressing diagnostically underserved critical care conditions such as sepsis, acute heart failure, and acute kidney injury.

SphingoTec is a privately held company with a long history of biomarker discovery, development and validation. We are the legal manufacturer of the CE IVD microtiter plate assays. Committed to providing solutions that meet and exceed customer and regulatory requirements, we manufacture our products in accordance with EN ISO 13485:2016.


Our investors share our vision of improving patient outcomes

SphingoTec in a nutshell

Our portfolio of tests supports better management of critically ill patients, where fast and reliable information is essential in taking treatment decisions. The solutions we have created combine scientific discoveries with medical research and robust technologies to support clinicians in improving disease management. We work together with internationally leading academic and non-academic medical centers, as well as with global IVD and pharma companies to bring these innovations closer to the patients. 

Investment Thesis

Global expansion

Through strategic partnerships and out-licensing of our biomarkers, we aim at making the innovations worldwide available.

Early stage opportunity

An opportunity of investment in more than 200 patents that could benefit over 60 million patients worldwide.

Skillful team

A skilled international team with a broad scope of experience committed to improve patient lives

An innovative portfolio

Innovative biomarkers for diagnosis, outcome prediction, and monitoring of mortality drivers in the intensive care unit.

Latest News

09. May 2023
SphingoTec has been successfully re-certified according to ISO 13485 and received its first IVDR certificate for its IVD product sphingotest® penKid®.
Read more
04. April 2023
The Acute Disease Quality Initiative (ADQI) has published a consensus statement that strongly recommends using innovative biomarkers to improve the management of sepsis-associated acute kidney injury (SA-AKI).
Read more
23. February 2023
Diagnostic company SphingoTec is pleased to announce the appointment of Dr. Florian Uhle as the company's new Medical Director. Dr. Uhle is a subject matter expert in translating innovations into routine clinical practice with a broad experience in both clinical and corporate settings.
Read more

Events & Expos

05. - 08. October 2023

14:04 - 15:05

Berlin, Germany

The Forum Nephrologie is a scientific, educational, and networking meeting and part of the 15. Jahrestagung der DGfN. The main congress program will kick off with an opening ceremony on Thursday,…

Read more
14. - 16. June 2023

14:00 - 15:01

Berlin, Germany

We are looking forward to participating for the first time in the 54th Joint Annual Meeting of the German Society of Internal Intensive Care and Emergency Medicine (DGIIN) and the Austrian Society of…

Read more
29. March - 01. April 2023

11:33 - 13:34

San Diego, USA

The CRRT conference provides a comprehensive review of advances in clinical care, research, and technology in critical care medicine with a focus on the kidney and renal support techniques. We are…

Read more

Contact Investor Relations

Do you have any questions or require more information? Please contact the Investor Relations Team, send us an e-mail or call us.

phone: + 49 (0)330 220 56 5 - 0

Dr. Angelo Moesslang

Chief Financial Officer and Managing Director

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now